Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Addressing challenges in palliative care

Dr Noel P. Pingoy - General Santos Doctors Hospital, General Santos City...

Addressing challenges in palliative care ( Dr Noel P. Pingoy - General Santos Doctors Hospital, General Santos City, Filipinas )

Improving cancer care access in the Philippines

Dr Jasmin R. Igama, Philippine Society of Medical Oncology, Manila, Philippines

Improving cancer care access in the Philippines ( Dr Jasmin R. Igama, Philippine Society of Medical Oncology, Manila, Philippines )

Understanding multiple myeloma: Challenges and solutions

Dr Flordeluna Z. Mesina, University of Santo Tomas Hospital - PCHTM, Manila...

Understanding multiple myeloma: Challenges and solutions ( Dr Flordeluna Z. Mesina, University of Santo Tomas Hospital - PCHTM, Manila, Philippines )

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in...

Dr Giulia Pasello - University of Padova, Padua, Italy

Adding durvalumab to neoadjuvant chemotherapy maintains quality of life in resectable NSCLC ( Dr Giulia Pasello - University of Padova, Padua, Italy )

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA...

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Digital pathology superior to manual SP263 PD-L1 TC scoring for stage II-IIIA high PD-L1 expression NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer

Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA

Taletrectinib superior to crizotinib in ROS1-positive non-small cell lung cancer ( Dr Misako Nagasaka - UCI School of Medicine, Irvine, USA )

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive...

Dr Sacha Rothschild - University of Basel, Basel, Switzerland

Perioperative durvalumab in addition to neoadjuvant chemotherapy shows positive results in patients with stage IIIa(N2) NSCLC ( Dr Sacha Rothschild - University of Basel, Basel, Switzerland )

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced...

Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany

Pembrolizumab plus cCRT continue to demonstrate antitumour activity in advanced NSCLC ( Prof Martin Reck - German Center of Lung Research, Grosshansdorf, Germany )

Treatment with BAY 2927088 led to durable responses in patients previously...

Prof Nicolas Girard - Institut Curie, Paris, France

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC ( Prof Nicolas Girard - Institut Curie, Paris, France )

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus...

Prof Nicolas Girard - Institut Curie, Paris, France

Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced ( Prof Nicolas Girard - Institut Curie, Paris, France )

Consolidation durvalumab after cCRT shows decreased disease progression in LS...

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC

Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

Subcutaneous pembrolizumab is a viable treatment option for mNSCLC ( Prof Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )

More from ecancer